Avricore Health Announces CEO Update Call on Sept. 22, 2022
20 Septembre 2022 - 2:00PM
AVRICORE HEALTH INC. (TSXV: AVCR) (the
"
Company" or “
AVCR”) is excited
to offer a live discussion on the Company’s current activities and
forward outlook as it executes a significant national scale-up of
its pharmacy-based point-of-care platform, HealthTab.
“We’re currently deploying a significant expansion of HealthTab
systems and we’re on track to achieve our revenue goals, as well as
getting to cash flow positivity,” said Avricore Health CEO, Hector
Bremner. “It’s an exciting time for the Company and we’re looking
forward to discussing the recent successes and future objectives.”
Call Details: September 22, 2022
@ 11:00am PT / 2:00pm ET via Zoom Register here to
receive login details: Investor@avricorehealth.com
Agenda:The 60-minute call agenda will be as
follows:10min: Opening Remarks / Team Introductions30Min: Overview
Presentation and Update20Min: Q&A We're looking forward to
seeing you there, please review our most recent investor
presentation here: www.avricore.com
HealthTab™ Market Fast Facts
- Point of Care Testing Market to reach $93.21 Billion USD in
2030 (Source)
- Nearly 13.6 Million Canadians expected to be diabetic or
prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have
pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed
with heart disease each year, often it’s only after a heart attack
they are diagnosed (Source)
- There are more than 10,000 pharmacies in Canada, 88,000
pharmacies in the US, nearly 12,000 in the UK.
About HealthTab™
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19.The HealthTab™ network model is unlike anything
in pharmacy today. It gives knowledgeable and trusted pharmacists a
greater role in primary care delivery, while empowering patients to
take more control of their health. It also reduces costs and
waiting times and provides many potential revenue streams including
equipment leasing & consumables, direct access testing, disease
prevention & management programs, sponsored health programs,
decentralized clinical trials, real world data (RWD) sets, and
third-party app integration through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service
innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™, a wholly owned subsidiary, the company’s
mission is to make actionable health information more accessible to
everyone by creating the world’s largest network of rapid testing
devices in community pharmacies.
Contact:
Avricore Health
Inc. Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com www.avricorehealth.com
Cautionary Note Regarding Forward-Looking
Statements Information in this press release that involves
Avricore Health's expectations, plans, intentions, or strategies
regarding the future are forward-looking statements that are not
facts and involve a number of risks and uncertainties. Avricore
Health generally uses words such as "outlook," "will," "could,"
"would," "might," "remains," "to be," "plans," "believes," "may,"
"expects," "intends," "anticipates," "estimate," "future,"
"positioned," "potential," "project," "remain," "scheduled," "set
to," "subject to," "upcoming," and similar expressions to help
identify forward-looking statements. In this press release,
forward-looking statements include statements regarding: the
completion of the placement and the expected timing thereof and the
Company's expected use of proceeds from the placement; the unique
features that the HealthTab™ platform offers to pharmacists and
patients. Forward-looking statements reflect the then-current
expectations, beliefs, assumptions, estimates and forecasts of
Avricore Health's management. The forward-looking statements in
this press release are based upon information available to Avricore
Health as of the date of this press release. Forward-looking
statements believed to be true when made may ultimately prove to be
incorrect. These statements are not guarantees of the future
performance of Avricore Health and are subject to a few risks,
uncertainties, and other factors, some of which are beyond its
control and may cause actual results to differ materially from
current expectations, including without limitation: failure to meet
regulatory requirements; changes in the market; potential downturns
in economic conditions; and other risk factors described in
Avricore's public filings. These forward-looking statements speak
only as of the date on which they are made, and the Company
undertakes no obligation to update them publicly to reflect new
information or the occurrence of future events or circumstances,
unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy
Avricore Health (TSXV:AVCR)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Avricore Health (TSXV:AVCR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024